These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21670086)

  • 1. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?
    Arteaga CL
    Clin Cancer Res; 2011 Aug; 17(15):4919-21. PubMed ID: 21670086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
    J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells.
    Raja SM; Clubb RJ; Bhattacharyya M; Dimri M; Cheng H; Pan W; Ortega-Cava C; Lakku-Reddi A; Naramura M; Band V; Band H
    Cancer Biol Ther; 2008 Oct; 7(10):1630-40. PubMed ID: 18769124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.
    Modi S; Saura C; Henderson C; Lin NU; Mahtani R; Goddard J; Rodenas E; Hudis C; O'Shaughnessy J; Baselga J
    Breast Cancer Res Treat; 2013 May; 139(1):107-13. PubMed ID: 23580070
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.
    Lu X; Xiao L; Wang L; Ruden DM
    Biochem Pharmacol; 2012 Apr; 83(8):995-1004. PubMed ID: 22120678
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
    Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
    Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T-DM1.
    Skeie M; Nikolaysen F; Chitano Y; Stang E
    J Cell Mol Med; 2020 Sep; 24(17):10258-10262. PubMed ID: 32672902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
    Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
    J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epidermal growth factor receptor 2-positive breast cancer: heat shock protein 90 overexpression, Ki67 proliferative index, and topoisomerase II-α co-amplification as predictors of pathologic complete response to neoadjuvant chemotherapy with trastuzumab and docetaxel.
    Bria E; Furlanetto J; Carbognin L; Brunelli M; Caliolo C; Nortilli R; Massari F; Pedron S; Manfrin E; Pellini F; Bonetti F; Sperduti I; Pollini GP; Scarpa A; Tortora G
    Clin Breast Cancer; 2015 Feb; 15(1):16-23. PubMed ID: 25034441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia--targeting of disease heterogeneity through direct and indirect antileukemic effects.
    Bruserud Ø; Hatfield KJ; Reikvam H
    Leuk Res; 2011 Sep; 35(9):1156-8. PubMed ID: 21802728
    [No Abstract]   [Full Text] [Related]  

  • 15. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    De Mattos-Arruda L; Cortes J
    Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
    Meng Q; Chen X; Sun L; Zhao C; Sui G; Cai L
    Mol Cell Biochem; 2011 Feb; 348(1-2):165-71. PubMed ID: 21082217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of metastatic HER2-positive breast cancer: present and future].
    Guiu S; Coudert B; Favier L; Arnould L; Fumoleau P
    Bull Cancer; 2010 Mar; 97(3):365-83. PubMed ID: 20176546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
    Cao X; Bloomston M; Zhang T; Frankel WL; Jia G; Wang B; Hall NC; Koch RM; Cheng H; Knopp MV; Sun D
    Clin Cancer Res; 2008 Mar; 14(6):1831-9. PubMed ID: 18347186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.
    Canonici A; Qadir Z; Conlon NT; Collins DM; O'Brien NA; Walsh N; Eustace AJ; O'Donovan N; Crown J
    Invest New Drugs; 2018 Aug; 36(4):581-589. PubMed ID: 29396630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumors.
    Jhaveri K; Miller K; Rosen L; Schneider B; Chap L; Hannah A; Zhong Z; Ma W; Hudis C; Modi S
    Clin Cancer Res; 2012 Sep; 18(18):5090-8. PubMed ID: 22781552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.